白蛋白结合型紫杉醇与多西紫杉醇联合顺铂诱导化疗治疗局部中晚期鼻咽癌的近期疗效比较  

Comparison of short-term efficacy between Albumin-Bound Paclitaxel and Docetaxel combined with Cisplatin in the treatment of locally middle and advanced nasopharyngeal carcinoma

作　　者：刘国英 夏伟雄[1] 张广顺 吕星[1] 李望忠 梁虎 郭翔[1] 向燕群[1] LIU Guoying;XIA Weixiong;ZHANG Guangshun;LYU Xing;LI Wangzhong;LIANG Hu;GUO Xiang;XIANG Yanqun(Department of Nasopharyngeal Carcinoma,Sun Yat-sen University Cancer Center,Guangdong Province,Guangzhou510060,China;Department of Medical Physicists’Room,Sun Yat-sen University Cancer Center,Guangdong Province,Guangzhou510060,China)

机构地区：[1]中山大学肿瘤防治中心鼻咽科,广东广州510060 [2]中山大学肿瘤防治中心物理室,广东广州510060

出　　处：《中国医药导报》2021年第8期90-93,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(81672680)。

摘　　要：目的比较白蛋白结合型紫杉醇联合顺铂(AC)与多西紫杉醇联合顺铂(DC)诱导化疗方案在局部中晚期鼻咽癌中的近期疗效。方法回顾性收集中山大学肿瘤防治中心2016年1月—2019年12月接受AC或DC诱导化疗的Ⅲ~Ⅳa期初治的170例鼻咽癌患者(115例接受AC治疗,55例接受DC治疗)的临床资料,经倾向评分匹配后,每组54例。比较两组诱导化疗后及放化疗结束后3个月的近期疗效,观察两组疾病进展和不良反应的发生情况。结果诱导化疗后及放化疗结束后,两组总有效率比较,差异无统计学意义(P>0.05)。两组疾病进展率比较,差异无统计学意义(P>0.05)。两组白细胞减少、中性粒细胞减少、贫血、血小板减少等毒副作用比较,差异无统计学意义(P>0.05)。结论AC在中晚期鼻咽癌中具有良好的耐受及疗效,与DC的疗效比较仍需更长时间随访进一步明确。Objective To compare the short-term efficacy of Albumin-Bound Paclitaxel combined with Cisplatin(AC)and Docetaxel combined with Cisplatin(DC)in the treatment of locally middle and advanced nasopharyngeal carcinoma.Methods From January 2016 to December 2019,the clinical data of stageⅢ-Ⅳa nasopharyngeal carcinoma patients who received AC or DC as induction chemotherapy from Sun Yat-sen University Cancer Center were collected retrospectively.After propensity score matching,there were 54 cases in each group.The short-term efficacy after induction chemotherapy and 3 months after completion of radio-chemotherapy were compared between the two groups,the disease progression and the incidence of adverse reaction in the two groups was observed.Results After induction chemotherapy and 3 months after completion of radio-chemotherapy,there were no significant differences in the total effective rate between two groups(P>0.05).There was no significant difference in disease progression rate between the two groups(P>0.05).There was no significant differences in the toxicity and side effects of leukopenia,neutropenia,anemia and thrombocytopenia between the two groups(P>0.05).Conclusion AC is well tolerated and effective in middle and advanced nasopharyngeal carcinoma,and the comparison of efficacy with DC still needs longer follow-up to be further confirmed.

关 键 词：白蛋白结合型紫杉醇 多西紫杉醇 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]